Page 2 - Anjali Singh

First wave of generic semaglutide approvals opens up India market

India has entered the first phase of generic semaglutide approvals, with CDSCO clearing multiple formulations for obesity and diabetes, paving the way for lower-cost GLP-1 therapies

Syngene downgrades its revenue guidance by 5% on Librela inventory impact

Syngene trims FY26 revenue guidance by up to 5% as inventory correction for veterinary drug Librela hits profits, even as core research and CDMO business grows

Cipla Q3 results: Net profit slumps 57% to ₹675 crore on US supply issues

Bets on respiratory product launches and peptides for growth

Syngene International Q3 net profit plunges 89%, revenue slips 3%

Librela inventory correction and one-time labour code costs weigh on earnings

Medical emergencies drive urban Indians to personal loans, says study

Rising medical costs and insurance gaps are pushing more urban Indians to take personal loans for healthcare, with reliance highest in Tier-I cities, a Paisabazaar study shows

Doctors warn of rising health and financial risks as air quality worsens

Study of doctors flags growing concern over worsening air quality in Indian cities, linking high AQI levels to chronic illnesses, rising healthcare costs and poor financial preparedness among patients

Toyota enters India's electric vehicle market with Urban Cruiser Ebella

Toyota Kirloskar Motor enters India's EV market with the Urban Cruiser Ebella, a born-electric SUV developed with Maruti Suzuki, as it pursues a multi-technology electrification strategy

Lamborghini posted record 2025 deliveries but India sales declined

Lamborghini delivered a record 10,747 vehicles globally in 2025, crossing the 10,000 mark for the first time, though sales in India slipped marginally amid uneven market conditions

Southern states hold the steering wheel in India's ePV transition

India's electric passenger vehicle registrations have surged over five years, with southern states consistently contributing about one-third of volumes

Sun Pharma terms $10 billion Organon acquisition reports 'speculative'

Sun Pharmaceutical said reports of a $10 billion acquisition of US-based Organon are speculative, adding there is no material information requiring disclosure to exchanges

FDA observation to hit Lanreotide supply; Cipla may face earnings risk

Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production following USFDA observations

Mahindra's XEV 9S, XUV 7XO clock nearly 94,000 bookings on launch day

Mahindra's newly launched XEV 9S and XUV 7XO SUVs drew strong initial demand, with nearly 94,000 bookings on the first day, translating into orders worth over Rs 20,500 crore

IPA members commit $50 million to set up pharma skilling academy PAGE

IPA member firms have committed $50 million to launch PAGE, an industry-led academy to boost pharmaceutical manufacturing skills, quality systems and regulatory compliance in India

Two-wheeler industry expects 6-9% growth in 2026 on GST cut, urban demand

India's two-wheeler industry is seen growing 6-9% in 2026, though a proposed ABS mandate for sub-125cc models could push up prices and temper volumes

2-wheeler industry eyes 6-9% growth in 2026 on GST-led affordability boost

India's two-wheeler industry is expected to grow 6-9% in 2026, aided by the GST cut, improved affordability and steady rural and urban demand, analysts said

India's diagnostics pivots to precision tests as high-value segments grow

Industry leaders say demand for these higher-value tests aimed at early disease detection, personalised treatment and long-term health management has been expanding far faster than routine pathology

SUV demand holds steady in used market despite GST-led price cuts

Despite GST relief making small cars cheaper, India's used-car market continues to favour SUVs, which are seeing faster inventory turnover and stronger residual values, industry executives say

Supriya Life Sciences bets on regulated markets with new facility

The Mumbai-based pharma company has commissioned a ₹165-crore formulations plant at Ambernath to support contract manufacturing and strengthen its presence in regulated global markets

Carmakers flex dealer, service networks to drive growth beyond metros

Network scale seen as central to tapping smaller markets

Mahindra bets on AI and skills to drive its 'Tech-First' transformation

Chairman Anand Mahindra says artificial intelligence, skills and education reforms will reshape work, talent flows and growth, as the Group sharpens its technology-focused strategy